Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone

Alessandra Vottero, Simona Pedori, Marta Verna, Blandina Pagano, Marco Cappa, Sandro Loche, Sergio Bernasconi, Lucia Ghizzoni

Research output: Contribution to journalArticle

Abstract

Context: GnRH analogs (GnRHa) are considered the treatment of choice for central precocious puberty (CPP). During GnRHa administration, the suppression of the pituitary-gonadal axis results in decreased rates of linear growth and skeletal maturation and in improved adult height. However, in some patients, the growth deceleration is so marked that the expected improvement in predicted adult height is not achieved. Objective: The objective of this study was to assess whether the addition of oxandrolone (Ox) may affect the height outcome of patients with CPP and growth deceleration during GnRHa treatment. Design: This was an open-label, clinical study. Setting: The study was performed at a pediatric endocrinology referral clinic. Patients: Twenty patients with CPP and marked growth deceleration during GnRHa treatment were studied. Interventions: Treatment consisted of GnRHa (Leuprorelina, 3.75 mg im every 28 d) alone (10 patients) or in combination with Ox (0.06 mg/kg·d by mouth) (10 patients). Main Outcome Measure: The main outcome measure was the patients' adult height. Results: The adult height of the patients treated with GnRHa plus Ox was significantly higher than pretreatment predicted adult height (162.6 ± 2.3 vs. 154.8 ± 1.7 cm, mean ± SEM; P <0.05) and target height (162.6 ± 2.3 vs. 158.0 ± 1.9; P > 0.05). Patients treated with GnRHa alone reached an adult height similar to the pretreatment predicted adult height (151.9 ± 1.2 vs. 155.4 ± 2.1 cm) but significantly lower than target height (151.9 ± 1.2 vs. 156.6 ± 1.4 cm; P <0.005). No side effects were recorded in either group of patients. Conclusions: Combined GnRHa and Ox therapy is a viable treatment option for children with CPP and marked growth deceleration during treatment with GnRHa alone.

Original languageEnglish
Pages (from-to)1284-1287
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number4
DOIs
Publication statusPublished - Apr 2006

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone'. Together they form a unique fingerprint.

  • Cite this